H.C. Wainwright raised the firm’s price target on Adma Biologics (ADMA) to $26 from $18 and keeps a Buy rating on the shares. The company reported a substantial top- and bottom-line outperformance and its guidance was increased yet again, the analyst tells investors in a research note.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter